Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has submitted the VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA) for regulatory approval. Notably, Lishman Global qualified for the NMPA’s “green channel” pathway, an expedited review process designed to fast-track innovative medical technologies addressing significant clinical needs. This designation is expected to streamline the regulatory timeline and facilitate faster access to the Chinese market.
This submission marks a critical step in Ventripoint’s global expansion strategy, targeting China’s vast and growing cardiology market. Cardiovascular disease is the leading cause of death in China, affecting approximately 330 million patients. Echocardiography is the most widely used cardiac imaging modality due to its cost-effectiveness, portability, and scalability across diverse healthcare settings. However, challenges such as variability in image interpretation and limited access to advanced modalities like MRI underscore the need for AI-driven tools that enhance diagnostic accuracy and workflow efficiency.
Ventripoint’s VMS+™ 4.0 addresses this need by delivering MRI-equivalent volumetric measurements from standard 2D echocardiography. Utilizing the company’s proprietary Knowledge Based Reconstruction technology, the platform enables precise assessment of all four heart chambers, supporting diagnosis and management of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
“We are excited to take this important step toward bringing VMS+™ 4.0 to the Chinese market,” said Paul Gibson, Chief Technology Officer of Lishman Global Inc. “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+™ 4.0 and provides a clear pathway to accelerated adoption. China’s scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology.”
“Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy,” said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. “China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly. By enabling more accurate and reproducible cardiac measurements using existing ultrasound infrastructure, VMS+ has the potential to significantly expand access to high-quality cardiac care.”
The company will provide further updates as the regulatory review process progresses. For more information, visit the original release on NewMediaWire.
